Amgen on Tuesday posted quarterly financial results that beat Wall Street expectations as a 9% increase in product sales ...

Amgen Inc (NASDAQ:AMGN) shares were slightly lower in premarket trading despite posting better-than-expected quarterly profit ...

Fifteen of the biotechnology company’s products delivered at least double-digit sales growth in the second quarter.

Amgen (NASDAQ:AMGN) reported second quarter earnings above expectations for the fourth time in a row, while also posting a ...

Non-GAAP earnings per share for Q2 2025 beat estimates by 14.0%, rising to $6.02 (non-GAAP) and up 21% year over year (non-GAAP). Revenue increased 9% to $9.2 billion, exceeding analyst expectations ...

Amgen, which is facing U.S. Federal Trade Commission (FTC) delays to its planned acquisition of Horizon Therapeutics, on Thursday reported higher quarterly profit on strong sales of treatments for ...

For the full year, Amgen narrowed its earnings outlook to between $19.20 and $20.00 per share, from $19.10 to $20.10. It also raised the midpoint of its revenue forecast and now expects $33 ...

Amgen narrowed its 2024 adjusted earnings estimate and now expects a profit of $19.10 to $20.10 per share, compared with its previous view of $19.00 to $20.20.

Amgen Inc on Thursday reported lower first-quarter profit as expenses rose and a 2% increase in sales of its own drugs was offset by lower revenue from its deal to manufacture COVID-19 antibody ...

Amgen posted a net profit of $1.17 billion, or $1.18 per share, compared with a profit of $1.02 billion, or 98 cents per share, a year ago, when it endured a particularly bad quarter.